CR20230262A - Inhibidor de integrina y usos de este - Google Patents
Inhibidor de integrina y usos de esteInfo
- Publication number
- CR20230262A CR20230262A CR20230262A CR20230262A CR20230262A CR 20230262 A CR20230262 A CR 20230262A CR 20230262 A CR20230262 A CR 20230262A CR 20230262 A CR20230262 A CR 20230262A CR 20230262 A CR20230262 A CR 20230262A
- Authority
- CR
- Costa Rica
- Prior art keywords
- crystalline forms
- methods
- inhibitors
- integrin inhibitor
- integrin
- Prior art date
Links
- 229940125798 integrin inhibitor Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002411 thermogravimetry Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente descripción se proporcionan inhibidores de integrina, composiciones de estos, y métodos para su uso. También se describen formas cristalinas de sales de los inhibidores, junto con métodos para preparar las formas cristalinas. Se proporcionan datos de difracción de polvo de rayos X, análisis termogravimétrico, y datos de calorimetría diferencial de barrido de las formas cristalinas. Los inhibidores de integrina son útiles en el tratamiento de, entre otras, las enfermedades fibróticas
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116042P | 2020-11-19 | 2020-11-19 | |
| PCT/US2021/072510 WO2022109598A1 (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230262A true CR20230262A (es) | 2023-07-26 |
Family
ID=81709878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230262A CR20230262A (es) | 2020-11-19 | 2021-11-19 | Inhibidor de integrina y usos de este |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12018025B2 (es) |
| EP (1) | EP4247472A4 (es) |
| JP (1) | JP2023550428A (es) |
| KR (1) | KR20230121761A (es) |
| CN (1) | CN116710169A (es) |
| AU (1) | AU2021381516A1 (es) |
| CA (1) | CA3173755A1 (es) |
| CL (1) | CL2023001418A1 (es) |
| CO (1) | CO2023006522A2 (es) |
| CR (1) | CR20230262A (es) |
| CU (1) | CU20230026A7 (es) |
| DO (1) | DOP2023000101A (es) |
| EC (1) | ECSP23045278A (es) |
| IL (1) | IL302651A (es) |
| MX (1) | MX2023005889A (es) |
| PE (1) | PE20240114A1 (es) |
| TW (1) | TW202235417A (es) |
| WO (1) | WO2022109598A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| US20240122930A1 (en) * | 2022-07-09 | 2024-04-18 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2024155965A2 (en) * | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052515A4 (en) | 2013-09-30 | 2017-03-15 | The Regents of the University of California | Anti-alphavbeta1 integrin compounds and methods |
| US10214522B2 (en) | 2015-03-10 | 2019-02-26 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
| CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| JP7092784B2 (ja) | 2017-02-28 | 2022-06-28 | モーフィック セラピューティック，インコーポレイテッド | αｖβ６インテグリン阻害剤 |
| JOP20200212A1 (ar) | 2018-03-07 | 2020-09-01 | Pliant Therapeutics Inc | مركبات حمض أميني وطرق استخدامها |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| KR20210029726A (ko) * | 2018-07-20 | 2021-03-16 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 촬상 패널, 촬상 장치 |
| EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CA3109534A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting .alpha.v .beta.6 integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| JP2022523621A (ja) * | 2018-12-28 | 2022-04-26 | ルナピービーシー | コミュニティデータの集約、完成、修正、および使用 |
| WO2020168359A1 (en) * | 2019-02-15 | 2020-08-20 | Gallagher John Henry | Oral hygiene appliance |
| EP3952902A4 (en) * | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND TREATMENT SCHEMES FOR AMINO ACID COMPOUNDS |
| CN115151566A (zh) | 2019-11-15 | 2022-10-04 | 普利安特治疗公司 | 用于活化整合素的组合物和方法 |
| AU2021268889A1 (en) * | 2020-05-07 | 2022-12-15 | Pliant Therapeutics, Inc. | Treatment of respiratory diseases with amino acid compounds |
| TWI843503B (zh) * | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US20230372434A1 (en) * | 2020-10-21 | 2023-11-23 | Cohbar, Inc. | Method of treating fibrosis with a combination therapy |
| AU2022265730A1 (en) | 2021-04-30 | 2023-11-16 | Pliant Therapeutics, Inc. | Expanded dosage regimens for integrin inhibitors |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| KR20240102970A (ko) | 2021-10-14 | 2024-07-03 | 플라이언트 테라퓨틱스, 인크. | 인테그린 억제제 및 다른 작용제와 조합된 그의 용도 |
| WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en active Pending
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en active Application Filing
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko active Pending
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 EP EP21895890.8A patent/EP4247472A4/en active Pending
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
-
2023
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
-
2024
- 2024-03-27 US US18/619,017 patent/US20240391914A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023006522A2 (es) | 2023-06-09 |
| US20220177468A1 (en) | 2022-06-09 |
| MX2023005889A (es) | 2023-06-06 |
| PE20240114A1 (es) | 2024-01-22 |
| EP4247472A4 (en) | 2024-10-09 |
| CL2023001418A1 (es) | 2023-10-30 |
| IL302651A (en) | 2023-07-01 |
| KR20230121761A (ko) | 2023-08-21 |
| US20240391914A1 (en) | 2024-11-28 |
| ECSP23045278A (es) | 2023-07-31 |
| AU2021381516A1 (en) | 2023-06-22 |
| CN116710169A (zh) | 2023-09-05 |
| DOP2023000101A (es) | 2023-09-29 |
| EP4247472A1 (en) | 2023-09-27 |
| TW202235417A (zh) | 2022-09-16 |
| WO2022109598A1 (en) | 2022-05-27 |
| US12018025B2 (en) | 2024-06-25 |
| JP2023550428A (ja) | 2023-12-01 |
| AU2021381516A9 (en) | 2024-10-24 |
| CA3173755A1 (en) | 2022-05-27 |
| CU20230026A7 (es) | 2024-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230262A (es) | Inhibidor de integrina y usos de este | |
| CR20200503A (es) | Inhibidores de cinasa dependientes de ciclina | |
| PH12021551529A1 (en) | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2022008456A (es) | Inhibidores de mek y usos terapeuticos de estos. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| CR20210031A (es) | Compuestos antagonistas de pcsk9 | |
| CA2962914C (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
| TN2010000049A1 (en) | Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2020010437A (es) | Inhibidores de axl cinasa y uso de los mismos. | |
| MX2021003422A (es) | Compuestos y metodos para aumentar la disponibilidad de nutrientes en el suelo. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX2020002824A (es) | Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia. | |
| MX2024000230A (es) | Inhibidores de cdk2. | |
| GEP20125433B (en) | α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT | |
| EP4480483A3 (en) | Solid state forms of belumosudil and belumosudil salts | |
| GEP20247655B (en) | Crystalline salt forms of kinase inhibitor | |
| CR20230604A (es) | Inhibidores de mutación de her2 | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2024010863A (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2). | |
| CO2021005077A2 (es) | Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma | |
| CR20240014A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| MX2010010561A (es) | Derivados tiazol de benzofenona utiles para inhibir la formacion del microtúbulo, y método para producir los mismos. |